Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 19, 2019 - Issue 11
Submit an article Journal homepage
808
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment

Maëlle le BesneraisDépartement de Médecine Interne, CHU Charles Nicolle, Rouen, France;Normandie Univ, UNIROUEN, INSERM U1096 EnVI, Rouen, France
,
Agnès VeyradierService d’Hématologie biologique and EA3518 Université Paris Diderot, Groupe Hospitalier Saint Louis – Lariboisière, Assistance Publique, Hôpitaux de Paris, Paris, France;French Reference Center for Thrombotic Microangiopathies, Hôpital Saint Antoine, Assistance Publique –Hôpitaux de Paris, Paris, France
,
Ygal BenhamouDépartement de Médecine Interne, CHU Charles Nicolle, Rouen, France;Normandie Univ, UNIROUEN, INSERM U1096 EnVI, Rouen, FranceCorrespondence[email protected]
&
Paul CoppoFrench Reference Center for Thrombotic Microangiopathies, Hôpital Saint Antoine, Assistance Publique –Hôpitaux de Paris, Paris, France;Département d’Hématologie clinique, Paris, FranceCorrespondence[email protected]
Pages 1127-1134 | Received 01 Apr 2019, Accepted 29 Jul 2019, Published online: 05 Aug 2019

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yoshiya Tanaka. (2023) Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis. Expert Opinion on Biological Therapy 23:7, pages 579-587.
Read now
Ismail Oran. (2021) Flow-diverting stent and delayed intracranial bleeding: the case for discussing acquired von Willebrand disease. Platelets 32:3, pages 432-435.
Read now

Articles from other publishers (8)

Jahir A. Soto-Mora, Lina M. Gómez-Espitia, Pieralessandro Lasalvia, Camilo A. Castellanos Moreno, Carol A. Casallas Vanegas & Sergio A. Londoño Gutiérrez. (2023) Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia. International Journal of Technology Assessment in Health Care 39:1.
Crossref
Gunnar Houen. 2022. Therapeutic Antibodies. Therapeutic Antibodies 1 25 .
Thinzar M. Lwin, Michael A. Turner, Siamak Amirfakhri, Hiroto Nishino, Pieterjan Debie, Bard C. Cosman, Robert M. Hoffman, Sophie Hernot & Michael Bouvet. (2021) Rapid tumor‐labeling kinetics with a site‐specific near‐infrared anti‐CEA nanobody in a patient‐derived orthotopic xenograft mouse model of colon cancer. Journal of Surgical Oncology 124:7, pages 1121-1127.
Crossref
Costanza Tripiciano, Paola Zangari, Mauro Montanari, Giovanna Leone, Laura Massella, Lucia Garaboldi, Michela Massoud, Stefano Lancellotti, Luisa Strocchio, Emma Concetta Manno, Paolo Palma, Tiziana Corsetti & Matteo Luciani. (2021) Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy. Frontiers in Pediatrics 9.
Crossref
Gennadii M. Galstyan, Alexei A. Maschan, Elizaveta E. Klebanova & Irina I. Kalinina. (2021) Treatment of thrombotic thrombocytopenic purpura. Terapevticheskii arkhiv 93:6, pages 736-745.
Crossref
Thinzar M. Lwin, Robert M. Hoffman & Michael Bouvet. (2021) Unique Benefits of Tumor-Specific Nanobodies for Fluorescence Guided Surgery. Biomolecules 11:2, pages 311.
Crossref
A. Ostuni, G. Tiscia, C. Battista, G. Favuzzi, V. Montinaro, V. Pronzo, F. Cappucci, L. Fischetti, L. Gesualdo & E. Grandone. (2021) Effective and safe off-label use of caplacizumab treatment in a middle-aged obese male. Transfusion Clinique et Biologique 28:1, pages 89-91.
Crossref
Katarina D. Kovacevic, Nina Buchtele, Christian Schoergenhofer, Ulla Derhaschnig, Georg Gelbenegger, Christine Brostjan, Shuhao Zhu, James C. Gilbert & Bernd Jilma. (2020) The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin. Scientific Reports 10:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.